Get the Stockscreener App
109.50
3.95%
-4.50
After Hours:
109.80
0.30
+0.27%
Axsome Therapeutics Inc Stock (AXSM) Latest News
Axsome Therapeutics (NASDAQ:AXSM) Price Target Raised to $190.00 at Truist Financial - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) Stock Price Expected to Rise, Mizuho Analyst Says - MarketBeat
Mizuho lifts Axsome stock target to $137, maintains Outperform - MSN
Calamos Advisors LLC Invests $1.08 Million in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Short Interest in Axsome Therapeutics, Inc. (NASDAQ:AXSM) Declines By 13.1% - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) Sets New 52-Week HighShould You Buy? - MarketBeat
HC Wainwright Forecasts Strong Price Appreciation for Axsome Therapeutics (NASDAQ:AXSM) Stock - MarketBeat
FY2024 Earnings Estimate for AXSM Issued By Leerink Partnrs - MarketBeat
RBC Capital lifts Axsome stock target to $143, sees launch potential - MSN
Axsome Therapeutics' SWOT analysis: CNS drug developer's stock poised for growth - MSN
(AXSM) Proactive Strategies - Stock Traders Daily
H.C. Wainwright lifts Axsome stock target to $190 on FDA nod - MSN
Axsome Therapeutics: Strategic Launch and Study Upside Drive Buy Rating - TipRanks
Truist Securities Adjusts Axsome Therapeutics Price Target to $190 From $180, Maintains Buy Rating - Marketscreener.com
Mizuho Raises Price Target on Axsome Therapeutics to $137 From $122, Keeps Outperform Rating - Marketscreener.com
RBC Lifts Price Target on Axsome Therapeutics to $143 From $139, Keeps Outperform Rating - Marketscreener.com
Axsome Therapeutics (NASDAQ:AXSM) Hits New 1-Year HighHere's What Happened - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) Given Outperform Rating at Royal Bank of Canada - MarketBeat
Moody Aldrich Partners LLC Sells 15,506 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Compass Therapeutics Stock Skyrockets 108% in a Month: Here's Why - MSN
Axsome gets FDA approval for Symbravo for migraine - MSN
Axsome Gets FDA Nod for New Migraine Drug Symbravo, Stock Rises - MSN
Musculoskeletal Pain Pipeline 2024: Therapies, MOA Insights, - openPR
FDA approves Axsome's novel migraine treatment SYMBRAVO By Investing.com - Investing.com Canada
Axsome’s Migraine Medicine Clears FDA Bar - BioSpace
Redemption complete for Axsome’s Symbravo in migraine - The Pharma Letter
Axsome Therapeutics' SWOT analysis: stock poised for growth amid CNS breakthroughs - MSN
Axsome Therapeutics Hosts SYMBRAVO® FDA Approval Virtual Investor Event with Expert Thought Leader - GlobeNewswire
FDA Victory: Axsome's Revolutionary Migraine Drug SYMBRAVO Gets Green LightTop Expert Reveals Clinical Impact - StockTitan
FDA approves new migraine treatment SYMBRAVO By Investing.com - Investing.com Canada
FDA approves new migraine treatment SYMBRAVO - MSN
Axsome Shares Up Post Market After Hitting Record High on FDA Approval - MarketWatch
US FDA approves Axsome Therapeutics' migraine drug - Reuters
Big Moves in Tech: Buying Apple, Selling Dell - The Globe and Mail
Axsome Therapeutics Announces FDA Approval of SYMBRAVO® (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults - The Manila Times
Axsome Therapeutics Announces FDA Approval of SYMBRAVO® - GlobeNewswire
Axsome Therapeutics Announces FDA Approval of SYMBRAVO® (meloxicam and rizatriptan) for the - The Bakersfield Californian
TD Cowen lifts Axsome stock target to $155, maintains Buy rating - MSN
Excessive Daytime Sleepiness Pipeline 2024: Key Companies, - openPR
Is Trump Media & Technology Group Stock a Buy? - The Globe and Mail
Axsome Therapeutics stock hits 52-week high at $105.18 By Investing.com - Investing.com South Africa
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):